FSRH Guideline (April 2019) Overweight, Obesity and Contraception

doi:10.1136/bmjsrh-2019-ooc

Cited by 14 publications

(6 citation statements)

References 217 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been established that the use of estrogen-based type of contraception in obese patients has a steady negative impact on the thromboembolic event risk [9]. The UK MEC advises against combined hormonal contraception (CHC) use in women with a body mass index (BMI) ≥ 35 kg/m 2 [24]. In addition to this, the use of most popular form of CHC, oral contraception, is associated with high risk of suboptimal efficiency, mostly due to malabsorption of medicines administered orally [11].…”

Section: Discussionmentioning

confidence: 99%

The Impact of Bariatric Surgery on Menstrual Abnormalities—a Cross-Sectional Study

2020

View full text Add to dashboard Cite

Introduction Obesity is associated with hyperestrogenism along with other hormonal abnormalities affecting the menstrual cycle. The most effective and decisive method of obesity treatment is bariatric surgery. The aim of this study was to analyze the impact of bariatric surgery on menstrual cycle, the incidence of menstrual abnormalities, hyperandrogenism manifestation, and contraception use. Materials and Methods It was a cross-sectional study of 515 pre-menopausal women who had undergone bariatric surgery between 1999 and 2017 in a bariatric center. Data was collected via anonymous questionnaire, and the questions covered a 1-year period before the surgery and the last year before questionnaire completion. Results Before the surgery, 38.6% of the patients reported irregular menstruations in comparison with 25.0% after bariatric surgery (RR = 0.65; 95%CI 0.53–0.79). The mean number of menstruations per year did not differ before and after surgery (10.2 ± 3.9 vs 10.4 ± 3.3; p < .45). There were no statistically significant differences in terms of prolonged menstruations, acne, and hirsutism prevalence. A total of 14.4% of patients before surgery reported estrogen-based contraception use in comparison with 15.0% after the surgery (p < .95). There were no significant differences in the frequency of OC use (11.0% before surgery vs 13.6% 12 months after the surgery vs 11.5% at the moment of survey administration; p < 0.46). Conclusion Bariatric surgery improves the regularity of the menstrual cycle in obese women in reproductive age. The lack of any changes in the combined hormonal contraception (CHC) use, especially OC, before and after bariatric surgery may be a result of a possibly low level of contraception counseling.

show abstract

Section: Discussionmentioning

confidence: 99%

The Impact of Bariatric Surgery on Menstrual Abnormalities—a Cross-Sectional Study

2020

View full text Add to dashboard Cite

show abstract

“…Следует помнить, что у пациенток с ожирением в качестве экстренной контрацепции предпочтительнее использование улипристала ацетата* в связи с отсутствием влияния повышения индекса массы тела (ИМТ) на эффективность препарата [ 14 ]. А в случае выбора девушкой с массой тела более 70 кг или ИМТ выше 26 кг/м² левоноргестрела необходимо увеличить дозу препарата вдвое (до 3,0 мг) [ 15 ].…”

unclassified

“…Однако назначение депо-препаратов медроксипрогестерона ацетата в подростковом возрасте не приветствуется в связи с их выраженным негативным воздействием на минеральную плотность костной ткани [ 23 ]. Информация о влиянии данного средства контрацепции на углеводный обмен (повышение как тощакового, так и постпрандиального уровня гликемии) [ 15 ] и массу тела [ 24 ] не позволяет говорить об их применении у пациенток с сахарным диабетом и ожирением.…”

unclassified

“…Метаанализ результатов 8 наблюдательных исследований не выявил связи применения гестагенсодержащих ВМС на риски венозных тромбоэмболий, однако необходимо заметить, что исследование проведено без учета ИМТ женщин [ 42 ]. Отсутствуют доказательства набора веса на фоне применения какого-либо из вариантов ВМС [ 15 ]. Дополнительной выгодой от применения данного вида контрацепции может стать снижение рисков гиперплазии и рака эндометрия, значимо повышенных у пациенток с ожирением [ 43 ].…”

unclassified

“…При анализе влияния гестагенсодержащих имплантов и оральных форм контрацепции навсю популяцию пользователей в целом не было получено убедительных доказательств их негативного влияния на массу тела при исходном повышении ИМТ. Неконтрацептивными эффектами при использовании данных средств может стать облегчение ситуации в плане дисменореи и болевого синдрома при овуляции, если эти отклонения не связаны с серьезной органической патологией [ 15 ].…”

unclassified

See 2 more Smart Citations

Contraception in adolescents with obesity and diabetes mellitus

Shaydullina

Валеева

Soubchankoulova

et al. 2022

Probl Endokrinol (Mosk)

View full text Add to dashboard Cite

Today most adolescents have their first sexual experience at the age of 15–19. However, only 44% of girls and young women (15–24 years old) report about contraception at that moment. A decision on pregnancy in adolescence is a difficult choice and any scenario may cause serious medical and social problems. Complications after an artificial abortion have a negative impact on a woman’s fertility. Diabetes mellitus type 1 and arterial hypertension accompanied with obesity within the metabolic syndrome are defined by the World Health Organization (WHO) as diseases, which increase risk of an unplanned pregnancy. The article consoders problems of interaction of a doctor and a teenage girl with endocrinopathy, when discussing her sexual health, the analysis of the literature reflecting the influence of contraception on the course of the underlying pathology is presented. The authors formed a list of drugs acceptable for use in diabetes and obesity based on assessment of risks and preferences from the use of different methods of fertility control. The work contains information about the procedure of starting contraception, the rules of future dynamic monitoring of the patient.

show abstract

Contraception for Adolescents and Young Women with Type 2 Diabetes–Specific Considerations

Merino

Codner

2022

Curr Diab Rep

View full text Add to dashboard Cite

FSRH Guideline (April 2019) Overweight, Obesity and Contraception

Cited by 14 publications

References 217 publications

The Impact of Bariatric Surgery on Menstrual Abnormalities—a Cross-Sectional Study

The Impact of Bariatric Surgery on Menstrual Abnormalities—a Cross-Sectional Study

Contraception in adolescents with obesity and diabetes mellitus

Contraception for Adolescents and Young Women with Type 2 Diabetes–Specific Considerations

Contact Info

Product

Resources

About